Sign In
Buy PHIO
$1.03
-0.0050 (-0.485%)
At Close: Jul 31, 2026
Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $2.5 Million Gross Proceeds
03:04pm, Friday, 25'th Jul 2025
King of Prussia, Pennsylvania--(Newsfile Corp. - July 25, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage siRNA biopharmaceutical company developing therapeutics using its propriet
Phio Pharmaceuticals Announces Pathology Results for Four of Five Patients in Fourth Cohort
12:36pm, Friday, 25'th Jul 2025
Complete Pathologic Response in patient with cutaneous squamous cell carcinoma Partial Response in Stage 4 metastatic Merkel cell patient King of Prussia, Pennsylvania--(Newsfile Corp. - July 25, 2025
Phio Pharmaceuticals Announces Agreement with U.S. Manufacturing Source for Drug Substance
07:45am, Friday, 25'th Jul 2025
Agreement covers contract development and manufacturing of lead compound PH-762 King of Prussia, Pennsylvania--(Newsfile Corp. - July 25, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinica
-Phio's lead clinical siRNA compound PH-762 demonstrates supportive safety profile in fourth cohort, permitting dose escalation in expected final cohort Marlborough, Massachusetts--(Newsfile Corp. - J
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
07:45am, Tuesday, 24'th Jun 2025
Registration Link for Presentation and live Q&A to take place, Monday, June 30, 2025 at 10:00 am EST Marlborough, Massachusetts--(Newsfile Corp. - June 24, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:
Phio Pharmaceuticals Announces Strategic Initiative to Create Awareness of the Comprehensive INTASYL siRNA Portfolio
07:45am, Friday, 06'th Jun 2025
- Robert Infarinato named VP, Strategic Development - Lisa Carson named as new VP, Finance and Administration Marlborough, Massachusetts--(Newsfile Corp. - June 6, 2025) - Phio Pharmaceuticals Corp. (
Best Value Stocks to Buy for May 28th
10:06am, Wednesday, 28'th May 2025
PHIO, ALRS and URBN made it to the Zacks Rank #1 (Strong Buy) value stocks list on May 28, 2025.
New Strong Buy Stocks for May 28th
05:40am, Wednesday, 28'th May 2025
PHIO, FLNG, BWB, ALRS and HALO have been added to the Zacks Rank #1 (Strong Buy) List on May 28, 2025.
Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference
07:45am, Monday, 19'th May 2025
Registration Link for Presentation to take place Thursday, May 22, 2025 at 10:00 AM ET Marlborough, Massachusetts--(Newsfile Corp. - May 19, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clin
Phio Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
04:15pm, Thursday, 15'th May 2025
Clinical trial advances for INSTASYL siRNA lead product candidate PH-762 4th Cohort enrolling and treating patients in on-going clinical study Marlborough, Massachusetts--(Newsfile Corp. - May 15, 202
Phio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical Trial
07:45am, Wednesday, 07'th May 2025
Complete Pathologic Response reported in 2 patients in the Third Cohort with cutaneous squamous cell carcinoma, complementing results in prior cohort Phio to present trial results to date at a podium
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
07:45am, Thursday, 01'st May 2025
Registration Link for Presentation and live Q&A to take place, Wednesday, May 7, 2025 at 2:00 pm EST Marlborough, Massachusetts--(Newsfile Corp. - May 1, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PH
Best Momentum Stocks to Buy for April 23rd
11:15am, Wednesday, 23'rd Apr 2025
CWST, and PHIO made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on April 23, 2025.
Best Value Stocks to Buy for April 23rd
07:46am, Wednesday, 23'rd Apr 2025
PHIO and TGS made it to the Zacks Rank #1 (Strong Buy) value stocks list on April 23, 2025.
PHIO Stock Soars as Safety Panel Clears Skin Cancer Drug for Next Dose
11:55am, Thursday, 10'th Apr 2025
Phio Pharmaceuticals stock rallies as safety committee gives green light to advance skin cancer candidate to next dose concentration in phase I study.
